Osteochondrodysplasia in a Scottish Fold Cat Treated with Radiation Therapy and Samarium-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylene-Phosphonic Acid.

Osteochondrodysplasia is a painful, progressive clinical syndrome unique to Scottish fold cats because of a heritable missense mutation in the TRPV4 gene. An 8 yr old male neutered Scottish fold cat was presented for a mass on his hind paw. The mass caused decreased mobility in the metatarsal region and digits and resulted in significant discomfort. Because of extensive skeletal abnormalities attributed to breed-related osteochondrodysplasia, the owner was reluctant to pursue amputation. Radiation therapy was pursued for palliation of pain. After coarsely fractionated external beam radiotherapy resulted in stabilization of the mass with eventual progression after 14 mo, samarium-153-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid was administered systemically, and the cat showed immediate, whole-body improvement in mobility. Concurrent intestinal and respiratory disease was evaluated and managed. Samarium-153-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid administration was repeated approximately every 6 mo for three treatments until the cat succumbed to thromboembolic disease attributed to previously diagnosed cardiac disease. Radiation therapy administered using either external beam or bone-seeking radioisotopes can be effective at palliating clinical signs associated with the skeletal abnormalities that accompany this disease.

Retrospective evaluation of the administration of 25% human albumin to dogs with protein-losing enteropathy: 21 cases (2003-2013).

OBJECTIVE: To describe the administration of 25% human serum albumin (HSA) to dogs diagnosed with idiopathic inflammatory bowel disease (IBD) and protein-losing enteropathy (PLE). The secondary objectives were to report any acute and delayed adverse events and the effect of corticosteroids on the development of these reactions. DESIGN: Retrospective study (2003-2013). SETTING: Private referral hospital. ANIMALS: Twenty-one client owned dogs diagnosed with PLE and idiopathic IBD that received ≥ 1 transfusion of 25% HSA. Dogs were included in the study if they had panhypoproteinemia, serum albumin concentration < 15.0 g/L [< 1.5 g/dL] or extravascular fluid accumulation, idiopathic IBD confirmed on histopathology, and complete medical records. INTERVENTIONS: None. MAIN RESULTS: Two of the 21 patients (9.5%) developed signs consistent with an acute reaction; 1 of these dogs was euthanized due to the severity of the reaction. Two patients (9.5%) showed signs consistent with a delayed reaction; 1 of these dogs was euthanized 5 days after the reaction, though it is unclear whether the reaction and the euthanasia were related. Corticosteroid administration did not appear to affect the occurrence of adverse reactions. CONCLUSIONS: This retrospective study demonstrated that the administration of 25% HSA to dogs with moderate to severe hypoalbuminemia from PLE was associated with occasional acute and delayed adverse events, some of which were severe or fatal.